Human
Area
Molecule
Species
Indication
Stage of Development
Preclinical
Phase I
Phase II
Phase III
Registration /
Marketing
Oncology
Tigilanol tiglate
Human
Head & Neck Cancer
Phase II monotherapy
Human
Head & Neck Cancer
Phase II + Keytruda®
Human
Soft Tissue Sarcoma
Phase II Pilot
Wounds
EBC-1013
Human
Venous Leg Ulcers
Phase I/IIa
Human
Other Wounds
Vet models
Veterinary
Area
Molecule
Species
Indication
Clinical
Registration /
Marketing
Oncology
Tigilanol tiglate
Canine
Mast Cell Tumor
STELFONTA® - marketed EU, UK, USA and Australia
Canine
Soft Tissue Sarcoma, Oral Melanoma
STELFONTA®
Equine
Sarcoid, Melanoma
STELFONTA®
Wounds
EBC-1013
Equine & Canine 
Acute / Chronic wounds
Pilot efficacy
Discovery
Area
Target
Collection
Lead optimisation
Initial
preclinical
Antibiotics
Multiple resistant organisms
Anti-inflammatories
Dermatology